Pfizer Just Locked Next Growth Path: What Investors Should Know
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Retirees benefit from selecting tax-efficient asset classes and optimized withdrawal sequencing. Learn which classes to favor and why.
23,930 articlesPfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Mega IPOs attract huge attention, but history teaches a sober lesson about valuation, timing, and long-term returns. ...
Treasury Secretary Scott Bessent pitched a bold growth plan: 3% GDP growth without higher inflation, anchored by AI-d...
Weekend reads aren’t just for leisure—they’re a powerful way to sharpen investing judgment. This guide blends long-fo...
Tech giant Alphabet leads a Thursday rally as its Gemini AI rollout gains traction. This piece breaks down what that ...
Carvana’s pivot from pure online disruption to owning physical dealerships is surprising. This piece breaks down why ...
A lithium-tech startup has reached unicorn status with a $1 billion valuation as demand for lithium accelerates acros...
Midyear market shifts put Buffett's moat concept under stress as MOAT slips while the broad market climbs. Here’s wha...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
Cantor Fitzgerald partners with Securitize to explore blockchain-native IPO shares, signaling a shift toward real-tim...
China’s export engine and structural advantages are shaping a landscape where trade deals matter less than the decade...
Grab is moving to pilot a new delivery robot in Singapore’s Punggol district by late 2026, aiming to relieve labor sh...